Pharma DECODED
Previous edition: 16 May 2024
Share article
Get the full version straight to your inbox.
Exclusive access to our best-in-class data & intelligence
Subscribe now
Moleculin begins NIH-funded Phase II glioblastoma treatment trial
The primary goal of the study is to measure progression-free survival.
Moleculin Biotech has announced the initiation of an investigator-initiated Phase II NU 21C06 clinical trial, funded by the National Institutes of Health (NIH), of WP1066 plus radiation therapy for adults with glioblastoma.
The trial is being conducted under Northwestern University's Investigative New Drug application, which references Moleculin's own US Food and Drug Administration (FDA)-cleared IND in April 2022.
Apart from NIH, BrainUp, a non-profit organisation focusing on creating awareness on brain cancer, is providing additional funding.
The open-label, multi-arm study is focusing on newly diagnosed patients with isocitrate dehydrogenase (IDH) wild-type, O6-methylguanine-DNA methyltransferase (MGMT)-unmethylated glioblastoma.
The primary goal of the study is to measure progression-free survival, while secondary outcomes include the analysis of the tumour microenvironment.
WP1066, an immune/transcription modulator, is designed to enhance the immune response to tumours by hindering regulatory T cells’ errant activity and oncogenic transcription factors.
The asset obtained orphan drug designation for the treatment of brain tumours and rare pediatric disease designation for three other paediatric indications.
Moleculin Biotech chairman and CEO Walter Klemp said: “We are continuing to evaluate WP1066 in additional indications including for the treatment of paediatric brain tumours and look forward to its continued development.”
In November last year, Moleculin reported positive initial efficacy data from the Phase II part of a Phase IB/II clinical trial of Annamycin to treat patients with soft tissue sarcoma (STS) lung metastases.
Latest news
KRAS inhibitors: The next frontier beckons
There has been several developments in the KRAS inhibitor space, shaping the KRAS inhibitors of the future.
FDA approves Bristol Myers Squibb's Breyanzi for follicular lymphoma
The approval is based on results from the open-label, global, multi-centre, single-arm Phase II TRANSCEND FL clinical trial.
Takeda's dengue vaccine obtains WHO prequalification
The TAK-003 vaccine targets all four virus serotypes.
FDA rejects label expansion for Dynavax's hepatitis B vaccine
The US agency rejected the expanded use of Dynavax’s vaccine for adults on haemodialysis, citing insufficient efficacy and safety data.
Tracking the opioid lawsuit settlements amidst calls for oversight
The US National Opioid Settlement is distributing more than $54 billion to communities grappling with the opioid crisis.
Vanda Pharmaceuticals reports positive data from motion sickness trial
In the trial, only 10.4% and 18.3% of the subjects reported vomiting on the 170mg and 85mg doses, respectively.
Allucent receives grant for decentralised Covid-19 vaccine trial
The company received the award to conduct a trial assessing correlates of protection following Covid-19 vaccination.
In our previous edition
Pharma Decoded
Circular RNA: Vaccines, therapeutics and biomarkers could be revolutionised
15 May 2024
Pharma Decoded
Sanofi to make €1bn biomanufacturing investment in France
14 May 2024
Pharma Decoded
RAPT terminates Phase II trials for lead candidate following clinical hold
13 May 2024
Newsletters in other sectors
Aerospace, Defence & Security
Automotive
Banking & Payments
Medical Devices
Oil & Gas
Travel and Tourism
Search companies, themes, reports, as well as actionable data & insights spanning 22 global industries
Access more premium companies when you subscribe to Explorer